Sold as Myozyme, Lumizyme. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 2 applications for Alglucosidase alfa (sold as Myozyme, Lumizyme), first approved Apr 28, 2006, with 1 new use approved and 0 published complete response letters.
| Lumizyme | Part D | $13.0M | −1% | 15 |
| Lumizyme | Part B | $10.2M | −40% | 17 |
| Treatment Frequency Reduction in Pompe DiseasePompe Disease (Late-onset), GAA Deficiency · Erasmus Medical Center | Phase 4 | Not yet recruiting | Aug 28, 2024 |
| A Global Prospective Observational Registry of Patients With Pompe DiseasePompe Disease · Amicus Therapeutics | — | Recruiting | Nov 7, 2023 |
| Higher Dose of Alglucosidase Alpha for Pompe DiseaseGlycogen Storage Disease Type II · Taipei Veterans General Hospital, Taiwan | — | Not yet recruiting | Aug 23, 2021 |
| PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)MPS I, MPS II · University of California, San Francisco | Phase 1 | Recruiting | Aug 31, 2020 |
| Developing a Management Approach for Patients With "Late-Onset" Pompe DiseasePompe Disease, Pompe Disease (Late-onset) · Duke University | — | Active, not recruiting | Oct 3, 2018 |
| A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase AlfaGlycogen Storage Disease Type II-Pompe's Disease · Genzyme, a Sanofi Company | Phase 2 | Active, not recruiting | Jan 12, 2017 |
| Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe DiseasePompe Disease · Duke University | — | Recruiting | Aug 15, 2012 |
| Pompe Pregnancy Sub-RegistryGlycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset) · Genzyme, a Sanofi Company | — | Recruiting | Dec 4, 2007 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA